8 results about "Hypertriglyceridemia" patented technology

This document describes the crystalline and liquid crystalline forms of sodium 25HC3S. This disclosure includes sodium 25HC3S in forms I, II, III, V, IX, XI, and XIII, and combinations thereof. Pharmaceutical formulations of the said forms or combinations thereof are further disclosed herein, as well as methods for treating or preventing diseases such as hypercholesterolemia, hypertriglyceridemia, and conditions associated with fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis). Methods for preparing 25HC3S are also provided.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.

The application discloses an aptamer for specifically distinguishing different glycosylation forms of ApoC-III, and a screening method and application thereof. The aptamer is specifically combined with non-glycosylated ApoC-III0, ApoC-III1, ApoC-III2, ApoC-III3 and total ApoC-III, and the nucleic acid sequence of the aptamer comprises any one or a combination of at least two of sequences shown in SEQ ID NO:1-SEQ ID NO:5. The aptamer has high affinity and strong specificity, can accurately distinguish the glycosylation spectrum of ApoC-III, and can be used for preparing a high-precision diagnostic kit for hypertriglyceridemia, atherosclerotic cardiovascular diseases and the like.

The present invention relates to an RNAi composition for inhibiting the expression of apolipoprotein C-III, and the use thereof. The RNAi composition can be used for treating and / or preventing APOC3-associated diseases or conditions such as cardiovascular diseases, hypertriglyceridemia and pancreatitis.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The present application provides a compound shown in formula I, wherein R1, R2, R3 are defined in the specification. The compound shown in formula I of the present application can effectively inhibit MOGAT2 enzyme activity, and has a clinical application prospect for treating and / or preventing obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, high VLDL, high fatty acid, diabetes or arteriosclerosis.

This disclosure relates to methods for using GLP-1 analogs and compositions thereof for the treatment of metabolic disorders such as obesity, diabetes mellitus, metabolic dysfunction-related fatty liver disease (MASLD), metabolic dysfunction-related steatohepatitis (MASH), and hypertriglyceridemia. More specifically, this disclosure relates to a method for treating obesity in a subject, comprising administering a therapeutically effective dose of GL0034 to the subject. This disclosure also relates to a method for treating a metabolic disorder in a subject requiring it, comprising administering a therapeutically effective dose of GL0034 to the subject. This disclosure further relates to compositions comprising GL0034 for the treatment of obesity, diabetes mellitus, or other metabolic disorders in a subject.